Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Papain-Like Proteases as Coronaviral Drug Targets: Current Inhibitors, Opportunities, and Limitations

28 Sept 2020

Abstract excerpt

Papain-like proteases (PLpro) of coronaviruses (CoVs) support viral reproduction and suppress the immune response of the host, which makes CoV PLpro perspective pharmaceutical targets. Their inhibition could both prevent viral replication and boost the immune system of the host, leading to the speedy recovery of the patient. Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to RNA Interference and Gene Delivery
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32998368
DOI: 10.3390/ph13100277

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Papain-Like Proteases as Coronaviral Drug Targets: Current Inhibitors, Opportunities, and LimitationsPMID 32998368Read ↗

Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors.Semantic proximity Read ↗

Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitorsSemantic proximity Read ↗

Discovery of novel papain-like protease inhibitors for potential treatment of COVID-19Semantic proximity Read ↗

Mutational profiling of SARS-CoV-2 papain-like protease reveals requirements for function, structure, and drug escape.Semantic proximity Read ↗

Recent progress in the discovery of inhibitors targeting coronavirus proteasesSemantic proximity Read ↗

Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19Semantic proximity Read ↗

Discovery of SARS-CoV-2 papain-like protease (PL <sup>pro</sup> ) inhibitors with efficacy in a murine infection modelSemantic proximity Read ↗

Potent and Selective Covalent Inhibition of the Papain-like Protease from SARS-CoV-2Semantic proximity Read ↗

Potent and Selective Covalent Inhibition of the Papain-like Protease from SARS-CoV-2Semantic proximity Read ↗

Antiviral activity of natural phenolic compounds in complex at an allosteric site of SARS-CoV-2 papain-like proteaseSemantic proximity Read ↗

Mutational Profiling of SARS-CoV-2 PLpro in human cells reveals requirements for function, structure, and drug escapeSemantic proximity Read ↗

3-Chymotrypsin-like Protease (3CLpro): Validation as a Molecular Target, Proposal of a Novel Catalytic Mechanism, and Inhibitors in Preclinical and Clinical TrialsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.